[Secretory activity of the adipocytes and comorbidities of obesity].
Fatty tissue synthesizes and secretes a wide range of products that may be directly involved in the pathogenesis of the complications associated with obesity. These so-called adipokines may trigger or sustain a chronic inflammatory process. By manipulating the secretory function of fat cells, it might in future be possible to prevent the development of the metabolic and cardiovascular complications of obesity. Current data already suggest that weight reduction and certain substances with an anti-inflammatory action reduce the risk for the metabolic and cardiovascular complications of obesity. To date, however, the evidence available is only indirect, and is insufficient to definitively establish causal relationships between certain secretory products of adipocytes and the comorbidities of adiposity. Further clinical studies are needed.
Skurk
T
T
Else-Kröner-Fresenius-Zentrum für Ernährungsmedizin, TU München. thomas.skurk@wzw.tum.de
Hauner
H
H
D017667:Adipocytes / Q000378:metabolism*; D052242:Adiponectin; D000273:Adipose Tissue / Q000378:metabolism*; D000818:Animals; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D020738:Leptin / Q000097:blood; D024821:Metabolic Syndrome / Q000503:physiopathology; D009765:Obesity / Q000097:blood / Q000150:complications* / Q000503:physiopathology*; D015849:Plasminogen Inactivators; D012307:Risk Factors; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control; D015431:Weight Loss
D052242:Adiponectin; D036341:Intercellular Signaling Peptides and Proteins; D015850:Interleukin-6; D020738:Leptin; D015849:Plasminogen Inactivators